MAY 07, 2015 02:21 PM PDT

Personal Profiling for Womb Cancer

About 2.8 percent of women will be diagnosed with endometrial cancer at some point in their lives, according to the National Cancer Institute. Contributing factors to the disease, in which malignant cells form in the tissues of the endometrium, include hormone therapy, obesity, high blood pressure and diabetes mellitus (http://seer.cancer.gov/statfacts/html/corp.html).
Genetic profiling of endometrial cancer can lead to more effective treatment.
The American Cancer Society says that cancer of the endometrium - the lining of the uterus or womb -- is the most common cancer of the female reproductive organs. The organization projects that in 2015 approximately 54,870 new cases of cancer of the body of the uterus (uterine body or corpus, including the endometrium) will be diagnosed, and 10,170 women will die from such cancers (http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-what-is-endometrial-cancer ).

Until now patients with endometrial cancer were classified as to their risk of disease in terms of a combination of clinical and tissue characteristics, such as their age, overall health data and the "growth and invasion of their tumor," according to researchers at the University of Manchester. Now these researchers can genetically profile high-risk womb cancer patients, enabling the patients to receive more appropriate treatment (University of Manchester. "Potential for a more personalized approach to womb cancer." ScienceDaily. ScienceDaily, 7 May 2015; www.sciencedaily.com/releases/2015/05/150507081741.htm).

While approximately 15 to 20 percent of endometrial cancer patients have high-risk disease, the optimal treatment approach for them has not been evident. The Manchester researchers have been studying genetic alterations in high-risk endometrial cancer, to determine whether they could be used to develop tumor subtypes. The team included Professor Richard Edmondson, Professor of Gynecological Oncology at The University of Manchester and Saint Mary's Hospital, as well as Dr Emma Crosbie and Professor Henry Kitchener from Manchester.

According to Prof. Edmondson, "Previous work, using comprehensive genetic profiling, has suggested that endometrial cancer can be classified into four subtypes. Our study has explored whether it is possible to use a simpler approach to detect subgroups in high risk patients."

Analyzing samples from 116 patients with endometrial cancer to find genetic variations, the international TransPORTEC research consortium discovered that genetic subtypes existed in their group of patients and that the classification procedure could predict which patients were more likely to relapse. The analysis enabled the researchers to identify distinctive genetic mutations that they could target with specific anti-cancer drugs.

Prof. Edmondson concluded, "It looks like these cancers classed as 'high-risk' in fact vary significantly in outcome. Our results could be used to refine risk assessment for endometrial cancer patients and allow doctors to choose either a less aggressive approach or more targeted treatment for individual patients." (University of Manchester. "Potential for a more personalized approach to womb cancer." ScienceDaily. ScienceDaily, 7 May 2015. www.sciencedaily.com/releases/2015/05/150507081741.htm).

Source: University of Manchester
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 05, 2018
Cancer
JUN 05, 2018
Early Breast Cancer Patients Do Not Gain Response Advantage with Chemotherapy
Phase III clinical trial research shows evidence that early breast cancer patients with common breast cancer type do not need chemotherapy & hormone therapy combo; hormone therapy is enough...
JUN 16, 2018
Clinical & Molecular DX
JUN 16, 2018
Nanoparticles Deliver "Theranostics" for Cancer Patients
New technology combing therapeutic agents and diagnostics (theranostics) can be used to deliver drugs to cancer cells. From the Moscow Institute of Physics...
JUL 13, 2018
Genetics & Genomics
JUL 13, 2018
Detecting Leukemia Before it Starts Growing
Researchers have found ways to identify people who may develop an aggressive type of blood cancer while they are still healthy....
AUG 07, 2018
Cancer
AUG 07, 2018
Is There a Best Time of Day to Administer Chemo?
A common hematologic cancer chemotherapy agent is looked at for its efficacy on solid tumors and specifically evaluates if delivery time during the day affects is anti-tumor activity....
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 05, 2018
Cancer
OCT 05, 2018
FDA approves a new drug for an advanced type of skin cancer
As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. A...
Loading Comments...